KLK3 and pachyonychia congenita: Treatment for PC is typically guided by key clinicopathological factors [3], including serum prostate-specific antigen (PSA) levels, clinical staging, biopsy Gleason sum (GS), patient age, and co-morbidities, as documented in the National Comprehensive Cancer Network (NCCN) guidelines [4] and the European Association of Urology guidelines [5].